Changeflow GovPing Healthcare & Life Sciences USPTO Patent Application for Anti-PD-1 Antibody...
Routine Notice Added Final

USPTO Patent Application for Anti-PD-1 Antibody-IL-2 Immunoconjugate Formulations

Favicon for changeflow.com USPTO Patent Applications - Peptides (C07K)
Published
Detected
Email

Summary

The USPTO has published a new patent application (US20260083857A1) for anti-PD-1 antibody-IL-2 immunoconjugate formulations. The application details stable pharmaceutical formulations comprising anti-human PD-1 antibody-modified human interleukin-2 immunoconjugates.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a publication of a new patent application filed with the USPTO, specifically application number US20260083857A1. The application, titled 'ANTI-PD-1 ANTIBODY-ATTENUATED IL-2 IMMUNOCONJUGATE FORMULATIONS,' was filed on September 22, 2025, and discloses stable pharmaceutical formulations involving anti-human PD-1 antibody-modified human interleukin-2 immunoconjugates.

As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it represents a new development in the field of immunoconjugates and may be of interest to pharmaceutical and biotechnology companies for potential licensing, competitive intelligence, or future product development strategies. No specific actions or penalties are associated with this publication.

Archived snapshot

Mar 26, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

ANTI-PD-1 ANTIBODY-ATTENUATED IL-2 IMMUNOCONJUGATE FORMULATIONS

Application US20260083857A1 Kind: A1 Mar 26, 2026

Inventors

Haichen Nie, Pragya Manandhar, Zaneta Maijorovaite, Wei Liu

Abstract

Disclosed herein are stable pharmaceutical formulations comprising anti-human PD-1 (hPD-1) antibody-modified human interleukin-2 (hIL-2) immunoconjugates and uses thereof.

CPC Classifications

A61K 47/6851 A61K 47/12 A61K 47/183 A61K 47/26 A61K 47/6813 C07K 14/55 C07K 16/2818 C07K 2317/92

Filing Date

2025-09-22

Application No.

19335771

View original document →

Named provisions

Inventors Abstract CPC Classifications

Get daily alerts for USPTO Patent Applications - Peptides (C07K)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
September 22nd, 2025
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260083857A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Development Pharmaceutical Formulation
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Biotechnology Intellectual Property

Get alerts for this source

We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!